Cosmos Health Signs LOI to Acquire Doc P...
Doc Pharma financial profile: approximately $24 million asset base, approximately $6.7 million in average annual revenue and approximately $3.2 million in average annual gross profit.Immediately accretive: expected to support margin expansion, profitability, and cash flow.Deepens vertical integration: expected to drive synergies, optimized production, economies of scale, expanded capacity, and a strengthened R&D engine.State-of-the-art production plant: GMP-licensed, approximately 59,000 square feet, built to the highest European standards, providing a clear growth avenue.Manufacturing excellence: a broad range of dosage forms, certified to GMP, ISO, Kosher, and Halal standards, with site registrations for the UAE, Qatar, Iraq and Lebanon.Boosts product portfolio: adds advanced and branded generics and OTC pharmaceutical products to the Cosmos Health portfolio. CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ('Cosmos Health' or the 'Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has entered into a non-binding letter of intent (the 'LOI') to acquire 100% of Doc Pharma S.A. ('Doc Pharma'), a fully licensed GMP pharmaceutical manufacturer.
Recommended for you
Bukken Box
PM Modi Italy visit LIVE: PM Modi meets Meloni in Rome, visits Colosseum ahead of key bilateral talks
"Very significant": Shringla hails PM Modi's five
Sensex slides 517 points on fears of fresh military action against Iran, elevated oil prices rattle markets
Solar, wind expansion in India set to trigger $10-15 billion land investments by 2030
Symphony expects better FY27 on summer demand recovery, lower finance costs
Meta Provides Rival AI Chatbots Limited Free WhatsApp Access In Europe: Report
Singapore a ‘major beneficiary’ as the wealthy move money out of troubled Gulf
What High Earners Actually Know About Money That Most People Don’t Talk About
BLS International shares soar 9% as Q4 PAT jumps 29% YoY to Rs 187 crore